Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Scinai Immunotherapeutics signed a definitive development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company. Contract includes about USD 5.1 million in committed base service fees, with revenue expected across 2026 and 2027. Committed customer orders rose to about USD 7.6 m
Scinai secured a $5.1 million development and clinical manufacturing agreement, expanding its CDMO business.
Scinai expanded its contract development and manufacturing business through a $5.1 million agreement for development and clinical manufacturing.